On Wednesday, Shares of Chesapeake Energy Corporation (NYSE:CHK), lost -2.51% to $7.38, as oil prices ended nearly 2 percent higher on Wednesday in volatile trade as rallying equities on Wall Street pulled crude up from lows after futures sank on concerns about global oversupply, according to Reuters.
U.S. stocks rose more than 1 percent in afternoon trading as technology stocks led a rebound from Tuesday’s steep losses and as China’s move to again support its financial markets eased investor concerns. Reuters Reports
Chesapeake Energy Corporation produces oil and natural gas through acquisition, exploration, and development of from underground reservoirs in the United States. It holds interests in natural gas resource plays, counting the Haynesville/Bossier Shales in northwestern Louisiana and East Texas.
Shares of JD.com, Inc. (NASDAQ:JD), declined -0.04% to $24.87, during its last trading session.
JD.com, declared partnerships with Australian brands Blackmores, a leading Australian natural health company, and Sanger Australia, the Australian meat sales and marketing business of the Bindaree Beef Group. Both brands will be available through JD.com’s direct sales channel and will use the company’s industry-leading same-day delivery capabilities. Sanger Australia will also leverage JD.com’s cold chain logistics network to ensure that its meat products are delivered fresh to Chinese customers from Australia.
The declarations follow the successful launch in late June of a dedicated Australian Mall for authentic imported Australian products on JD.com’s cross-border platform, JD Worldwide. Since its launch, dozens of Australian brands have successfully sold their products to Chinese consumers through Australian Mall. The most popular product categories in the first two months of the program comprise healthcare, baby care products and fresh food.
JD.com, Inc., through its auxiliaries, operates as an online direct sales company in the People’s Republic of China. It primarily offers electronics and home appliances products; and general merchandise products, counting audio and video products, and books.
Finally, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), ended its last trade with 3.80% gain, and closed at $101.62.
Alnylam Pharmaceuticals and The Medicines Company (NASDAQ:MDCO), a global biopharmaceutical company focusing on saving lives, alleviating suffering and contributing to the economics of healthcare by focusing on the world’s leading acute/intensive care hospitals, declared recently positive initial results from their ongoing Phase 1 clinical trial with ALN-PCSsc at ESC Congress 2015 held August 29 – September 2, 2015, in London. ALN-PCSsc is an investigational RNAi therapeutic targeting PCSK9 – a genetically validated protein regulator of LDL receptor metabolism – being developed for the treatment of hypercholesterolemia. In contrast to anti-PCSK9 monoclonal antibodies (MAbs) that bind to PCSK9 in blood, ALN-PCSsc is a first-in-class investigational medicine that acts by turning off PCSK9 synthesis in the liver.
In the Phase 1 study, subcutaneous administration of ALN-PCSsc resulted in an up to 83% lowering of LDL-C, with an up to 64 ± 5% mean maximum reduction, comparable to published results for anti-PCSK9 MAbs (Zhang XL., et al., BMC Med, 2015). Similar reductions in LDL-C were seen in patients on and off concomitant statin therapy. The effects of ALN-PCSsc were highly durable, with clinically noteworthy and clamped reductions in LDL-C maintained for over 140 days, supportive of a once-quarterly and possibly bi-annual subcutaneous dose regimen. Maximal lowering effects on LDL-C were consistently achieved at a dose of 300 mg associated with a low injection volume of 1.5 mL; this dose was significantly below the 800 mg top dose studied per the Phase 1 protocol. Importantly, ALN-PCSsc was generally well tolerated with no clinically noteworthydrug-related adverse events. The development leadership of ALN-PCSsc now transitions from Alnylam to The Medicines Company, who together declare recently initiation of the ORIONTM development program, with an initial Phase 2 study planned to start by end-2015 and a Phase 3 study predictable to start by end-2017. ORION is also predictable to comprise a comparative study of ALN-PCSsc with anti-PCSK9 MAbs.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
